Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sustained Release Oral Formulation of Carbidopa/Levodopa in Healthy Volunteers
NCT05471609Phase 1Completed
- Sponsor
- University of Minnesota
- Start
- Jun 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of carbidopa and levodopa in Parkinson's disease (PD) (2 arms), sponsored by University of Minnesota. Primary endpoint: Carbidopa/levodopa serum level at 6 hours. Started Jun 2025; status: completed.
02
Drugs
carbidopalevodopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05471609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05471609.